Drug intelligence / Profile preview

DuoCAR20.19.22-D95

Development stage: Phase 1
Lead developer: University of Kansas Medical Center
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

DuoCAR20.19.22-D95 is an investigational autologous CAR-T cell therapy developed for the treatment of relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and various forms of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphoma, marginal zone B-cell lymphoma, and mediastinal large B-cell lymphoma[1][3][5]. This therapy involves engineering a patient's own T cells to express chimeric antigen receptors (CARs) that target multiple antigens—specifically CD19, CD20, and CD22—on the surface of malignant B cells[3][5]. The multi-targeting approach aims to reduce the risk of tumor escape due to antigen loss or downregulation. The drug is currently being evaluated in Phase 1 clinical trials in the United States to determine its safety profile, maximum tolerated dose (MTD), and initial efficacy in adult patients with relapsed or refractory disease[1][2][7]. The University of Kansas Medical Center is leading its development.

Other names: Trispecific CD19, CD20, CD22-targeting CAR-Ts

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on DuoCAR20.19.22-D95.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DuoCAR20.19.22-D95.

Explore the full profile